A Combination Chemotherapy Protocol with Dose Intensification and Autologous Bone Marrow Transplant (VELCAP‐HDC) for Canine Lymphoma
A Combination Chemotherapy Protocol with Dose Intensification and Autologous Bone Marrow Transplant (VELCAP‐HDC) for Canine Lymphoma
复制标题
犬淋巴瘤的剂量强化和自体骨髓移植 (VELCAP-HDC) 联合化疗方案
DOI：
--
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
P. Quesenberry
中科院分区：
文献类型：
--
作者：
A. Frimberger;A. Moore;K. Rassnick;S. Cotter;Jennifer O'Sullivan;P. Quesenberry
28只患有淋巴瘤的狗接受了为期12周的5种药物化疗方案，最后采用自体骨髓移植支持的高剂量环磷酰胺。使用剂量递增设计确定该情况下环磷酰胺的最大耐受剂量（MTD）。给予三种环磷酰胺剂量水平：300 mg/ m2 IV（第1组，3只犬）、400 mg/m2 IV（第2组，12只犬）和500 mg/m2 IV（第3组，13只犬）; MTD为500 mg/m2 IV。毒性常见但轻微，剂量限制性毒性为骨髓抑制，特别是中性粒细胞减少。无犬因给药相关毒性而死亡。第3组中的一只犬出现发热、中性粒细胞减少和推测的脓毒症，并对常规管理迅速作出反应。没有其他狗需要住院治疗。与较低剂量组合（第1组和第2组）相比，较低分期和较高环磷酰胺剂量（均为增加剂量[研究组1-3]和最高剂量[第3组]）与较长缓解持续时间显著相关（所有P < .0001）。第3组犬的中位缓解持续时间为54周，而第1组和第2组合并犬的中位缓解持续时间为21周。与较长生存时间相关的因素是分期较低（P = 0.042）和环磷酰胺剂量较高（均增加剂量[研究组1-3]，最高剂量[组3]与较低剂量组合[组1和2]相比）（P = 0.027）。第3组犬的中位生存时间为139周，而第1组和第2组犬的中位生存时间分别为43周和68周。
Twenty-eight dogs with lymphoma were treated with a 12-week, 5-drug chemotherapy protocol concluding with high-dose cyclophosphamide supported by autologous bone marrow transplants. A dose escalation design was used to determine the maximum tolerated cyclophosphamide dose (MTD) in this setting. Three cyclophosphamide dose levels were given: 300 mg/ m2 IV (groupl, 3 dogs), 400 mg/m2 IV (group 2, 12 dogs), and 500 mg/m2 IV (group 3, 13 dogs); and the MTD was 500 mg/m2 IV. Toxicity was common but mild, and the dose-limiting toxicity was myelosuppression, specifically neutropenia. No dog died as a result of treatment-related toxicity. One dog in group 3 developed fever, neutropenia, and presumed sepsis and responded promptly to routine management. No other dog required hospitalization. Lower stage and higher cyclophosphamide dose (both increasing dose [study groups 1-3], and the highest dose [group 3]) compared with the lower doses combined (groups 1 and 2) were significantly associated with longer remission duration (all P < .0001). Median remission duration for dogs in group 3 was 54 weeks, compared with 21 weeks for dogs in groups 1 and 2 combined. Factors associated with longer survival time were lower stage (P = .042) and higher cyclophosphamide dose (both increasing dose [study groups 1-3], and the highest dose [group 3] compared with the lower doses combined [groups 1 and 2]) (P = .027). Median survival time for dogs in group 3 was 139 weeks, compared with 43 weeks and 68 weeks for dogs in groups 1 and 2, respectively.
登录
查看更多内容
自体骨髓移植作为犬淋巴瘤的巩固治疗：各种全身照射方案的疗效和毒性。
影响因子：
1
作者：
Deeg,HJ;Appelbaum,FR;Weiden,PL;Hackman,RC;Graham,TC;Storb,RC
通讯作者：
Storb,RC
用抗 Ia 单克隆抗体对骨髓进行细胞溶解处理后，自体骨髓重建失败。
影响因子：
20.3
作者：
Szer,J;Deeg,HJ;Appelbaum,FR;Storb,R
通讯作者：
Storb,R
DOI：
--
发表时间：
1990
期刊：
Laboratory animal science
影响因子：
--
作者：
Ladiges,WC;Storb,R;Thomas,ED
通讯作者：
Thomas,ED
使用2-巯基乙磺酸钠预防环磷酰胺膀胱炎。
DOI：
10.1016/s0022-5347(17)50729-6
发表时间：
1984
期刊：
The Journal of urology
影响因子：
--
作者：
Ehrlich,RM;Freedman,A;Goldsobel,AB;Stiehm,ER
通讯作者：
Stiehm,ER
通过 c-kit 配体挽救抗 MHC II 类抗体介导的骨髓移植衰竭。
影响因子：
20.3
作者：
Deeg,HJ;Beckham,C;Huss,R;Myerson,D;Greinix,H;Appelbaum,FR;Graham,T;Schuening,F;Storb,R
通讯作者：
Storb,R